Fuji Pharma Co., Ltd. (TYO:4554)
Japan · Delayed Price · Currency is JPY 2,339.00
+48.00 (2.10%)
May 29, 2026, 3:30 PM JST
Fuji Pharma Income Statement
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| 57,298 | 51,677 | 46,138 | 40,889 | 35,426 | 33,990 | |
Revenue Growth (YoY) | 17.31% | 12.01% | 12.84% | 15.42% | 4.23% | 0.58% |
Cost of Revenue | 34,091 | 30,914 | 28,294 | 24,374 | 20,867 | 19,239 |
Gross Profit | 23,207 | 20,763 | 17,844 | 16,515 | 14,559 | 14,751 |
Selling, General & Admin | 11,308 | 10,957 | 9,231 | 8,331 | 7,355 | 8,340 |
Research & Development | 3,344 | 3,344 | 3,401 | 3,184 | 2,485 | 2,446 |
Amortization of Goodwill & Intangibles | 90 | 90 | 337 | 316 | 283 | 278 |
Operating Expenses | 16,124 | 15,773 | 13,963 | 12,656 | 10,781 | 11,402 |
Operating Income | 7,083 | 4,990 | 3,881 | 3,859 | 3,778 | 3,349 |
Interest Expense | -379 | -330 | -196 | -121 | -77 | -53 |
Interest & Investment Income | - | - | - | 77 | 43 | 7 |
Currency Exchange Gain (Loss) | 51 | 35 | 74 | 127 | 227 | -48 |
Other Non Operating Income (Expenses) | 115 | 85 | 53 | 212 | 39 | -6 |
EBT Excluding Unusual Items | 6,870 | 4,780 | 3,812 | 4,154 | 4,010 | 3,249 |
Gain (Loss) on Sale of Investments | -3,519 | - | 3,118 | - | - | 153 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 2 |
Asset Writedown | -417 | -776 | 572 | 364 | -288 | -33 |
Legal Settlements | - | - | - | -120 | - | - |
Other Unusual Items | -1 | -4 | 772 | - | - | -1 |
Pretax Income | 2,933 | 4,000 | 8,274 | 4,398 | 3,722 | 3,370 |
Income Tax Expense | 507 | 1,000 | 2,128 | 963 | 1,026 | 938 |
Net Income | 2,426 | 3,000 | 6,146 | 3,435 | 2,696 | 2,432 |
Net Income to Common | 2,426 | 3,000 | 6,146 | 3,435 | 2,696 | 2,432 |
Net Income Growth | -23.61% | -51.19% | 78.92% | 27.41% | 10.85% | 16.64% |
Shares Outstanding (Basic) | 25 | 24 | 24 | 24 | 24 | 27 |
Shares Outstanding (Diluted) | 25 | 24 | 24 | 24 | 24 | 27 |
Shares Change (YoY) | 1.15% | 0.38% | 0.04% | 0.03% | -9.58% | -13.77% |
EPS (Basic) | 98.53 | 122.93 | 252.81 | 141.35 | 110.98 | 90.52 |
EPS (Diluted) | 98.53 | 122.93 | 252.81 | 141.35 | 110.98 | 90.52 |
EPS Growth | -24.48% | -51.37% | 78.86% | 27.37% | 22.60% | 35.27% |
Free Cash Flow | 5,508 | 3,820 | 1,373 | -1,410 | -5,755 | 2,204 |
Free Cash Flow Per Share | 223.71 | 156.54 | 56.48 | -58.02 | -236.90 | 82.03 |
Dividend Per Share | 25.500 | 45.500 | 42.500 | 37.000 | 35.000 | 29.000 |
Dividend Growth | -40.00% | 7.06% | 14.87% | 5.71% | 20.69% | - |
Gross Margin | 40.50% | 40.18% | 38.67% | 40.39% | 41.10% | 43.40% |
Operating Margin | 12.36% | 9.66% | 8.41% | 9.44% | 10.66% | 9.85% |
Profit Margin | 4.23% | 5.80% | 13.32% | 8.40% | 7.61% | 7.16% |
Free Cash Flow Margin | 9.61% | 7.39% | 2.98% | -3.45% | -16.25% | 6.48% |
EBITDA | 11,113 | 8,955 | 7,561 | 6,882 | 6,523 | 5,455 |
EBITDA Margin | 19.39% | 17.33% | 16.39% | 16.83% | 18.41% | 16.05% |
D&A For EBITDA | 4,030 | 3,965 | 3,680 | 3,023 | 2,745 | 2,106 |
EBIT | 7,083 | 4,990 | 3,881 | 3,859 | 3,778 | 3,349 |
EBIT Margin | 12.36% | 9.66% | 8.41% | 9.44% | 10.66% | 9.85% |
Effective Tax Rate | 17.29% | 25.00% | 25.72% | 21.90% | 27.57% | 27.83% |